ANDA "Major/Minor" Amendment Reclassification Proposed By FDA
This article was originally published in The Tan Sheet
Executive Summary
FDA's Office of Generic Drugs may change its classification of ANDA amendments to allow the vast majority to be treated as "minor" amendments receiving 60-day reviews.